Liu Li, Heng Wei
Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):89-91. doi: 10.3779/j.issn.1009-3419.2015.02.07.
In recent years, with the deepening of the research of molecular biology, targeted therapy has become one of the trend of lung cancer treatment. The individualized treatment of lung cancer is attached great importance at present. Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase (EML4-ALK) as a new biological marker is a hot topic in the field of lung cancer treatment. Meanwhile, with the improvement of anticancer treatment and survival, the incidence of multiple primary carcinomas (MPC) has become increasingly. But the report that malignant lymphoma complicated with lung adenocarcinoma harboring EML4-ALK fusion gene in one individual is rare. Here, we report an EML4-ALK positive non-small cell lung cancer (NSCLC) in a patient previously diagnosed with T cell lymphoma and review literature on metachronous lung cancer complicating with lymphoma.
近年来,随着分子生物学研究的深入,靶向治疗已成为肺癌治疗的趋势之一。目前,肺癌的个体化治疗备受重视。棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)作为一种新的生物标志物,是肺癌治疗领域的研究热点。同时,随着抗癌治疗效果的提高和患者生存期的延长,多原发性癌(MPC)的发病率日益增加。但关于同一患者恶性淋巴瘤合并携带EML4-ALK融合基因的肺腺癌的报道较为罕见。在此,我们报告1例先前诊断为T细胞淋巴瘤的患者发生EML4-ALK阳性非小细胞肺癌(NSCLC),并复习关于异时性肺癌合并淋巴瘤的文献。